Zoetis (ZTS) In Focus On Burry Buying As Investors Weigh An Undervalued Story

Zoetis (ZTS) is back in focus after Michael Burry increased his position in the stock, just as the animal health company heads toward an early August earnings report that many investors are watching closely.

See our latest analysis for Zoetis.

At a share price of $77.29, Zoetis has seen a 6.68% 1 month share price return and a 2.57% 7 day share price return, yet its 1 year total shareholder return has declined 46.55%. This points to fading longer term momentum even as short term interest picks up ahead of earnings and Burry’s increased position.

If this shift toward healthcare has your attention, it could be a good moment to widen your watchlist with 41 healthcare AI stocks

Zoetis has delivered modest recent gains even as the 1 year return remains sharply lower, which leaves an open question: Are buyers now responding to improving business fundamentals, or is this mainly a sentiment swing that the valuation section needs to unpack next?

Most Popular Narrative: 16.8% Undervalued

Zoetis is trading at $77.29 while the most followed narrative pegs fair value at $92.92, which puts that viewpoint clearly on the undervalued side.

World's leading animal pharma company at 13x PE with 9% EPS growth. Occasionally something crosses my eye which screens well, but after some work is done it isn’t interesting enough to warrant writing about it as a paid article. Zoetis is one such stock. There are hints of genuine value in the position, but I figured there wouldn’t be enough people interested in their single-digit growth. I already finished the analysis halfway, so I thought I’d share it with those who are interested in it.

Read the complete narrative. Read the complete narrative.

The fair value call here leans heavily on steady earnings, healthy margins and a patient view on capital allocation. Curious which specific assumptions drive that gap to $92.92?

Result: Fair Value of $92.92 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to watch Zoetis’ reliance on a few key product lines and customers, as well as any further weakness in US Companion Animal revenues.

Find out about the key risks to this Zoetis narrative.

Next Steps

With mixed signals around Zoetis in this article, now is a good time to act, review the data yourself, and weigh both sides using 5 key rewards and 1 important warning sign

Looking for more investment ideas beyond Zoetis?

Do not stop with Zoetis. Use the Simply Wall Street Screener to spot other opportunities that fit your goals before they move out of reach.

• Target more resilient payers by reviewing companies that show up in the 9 dividend fortresses and see which ones match your income expectations.
• Hunt for potentially mispriced quality by scanning the screener containing 19 high quality undiscovered gems and compare stories that the market may not be focusing on yet.
• Prioritise capital protection by checking companies highlighted in the 81 resilient stocks with low risk scores so you can focus on ideas that line up with a lower risk profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com